Amneal Pharmaceuticals (AMRX) EBITDA (2017 - 2026)
Amneal Pharmaceuticals (AMRX) EBITDA from Jun 30, 2017 to Mar 31, 2026. The TTM Amneal Pharmaceuticals (AMRX) EBITDA is $491M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Amneal Pharmaceuticals (AMRX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +16.16% |
| 5 Years TTM | +26.35% |
Annual EBITDA change of Amneal Pharmaceuticals (AMRX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $64M | -85.73% |
| 2025 | $451M | +44.71% |
| 2024 | $312M | +15.29% |
| 2023 | $271M | -1108.46% |
| 2022 | -$27M | -112.57% |
| 2021 | $213M | +40.81% |
| 2020 | $152M | -181.75% |
| 2019 | -$185M | -514.39% |
| 2018 | $45M | -84.41% |
| 2017 | $287M | -8.63% |
| 2016 | $314M | N/A |
Comparison Amneal Pharmaceuticals (AMRX) five years EBITDA CAGR with competitors
Amneal Pharmaceuticals (AMRX) five years EBITDA CAGR is 26.35%.